Comparison of two drugs, Lignocaine and Ketamine intravenous infusion in management of difficult cancer pain

Comparison of Ketamine Vs Lignocaine intravenous infusion in refractory cancer pain - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058966

Enrollment

Registered

2023-10-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Lignocaine: Inj Lignocaine 2mg/kg/hr over 6hrs 2 infusions with 12hrs apart-FOLLOW UP for 6weeks Control Intervention1: Ketamine: Inj Ketamine 0.3mg/kg/hr over 6hrs 2 infusions with 12

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Refractory cancer pain with NRS >6-7/10 despite optimal opioid drugs (OME >300 mg / day) Patients with refractory neuropathic/mixed pain Patients with life span >8weeks

Exclusion criteria

Exclusion criteria: H/O psychosis Any liver, kidney and heart abnormalities Patients with altered cognitive function H/O drugs hypersensitivity Patients not giving consent

Design outcomes

Primary

Measure	Time frame
Comparison of Ketamine Vs Lignocaine intravenous infusion in refractory cancer pain in reducing severity of pain atleast by 50%Timepoint: 1 year	—

Secondary

Measure	Time frame
1.Comparison of side effect profile & tolerability of both drugs 2.Comparison of time interval in both drugs till next relapse of acute pain crisisTimepoint: 1 year	—

Countries

India

Contacts

Public ContactPulluri Sai Sowmya

Baswatarakam Indo American cancer Hospital and research Institute

drprawin78@gmail.com9959893915

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026